AT
Auron Therapeutics, Inc.
SEC filingBiotechnology · Wellesley, MA
Amount raised$7.1Msold at filing
Total offering$12M$4.9M still open
Investors in the raise14count reported to the SEC
FiledAug 13, 2026first sale Aug 10, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Briggs Duncan MorrisonDirector
Pini Duncan OrbachDirector
Serge Duncan MesserlianDirector
Victoria Duncan RichonDirector
Alexandra CantleyDirector
Anna Duncan FrenchDirector
Katharine YenExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.